This page shows the latest macular degeneration news and features for those working in and with pharma, biotech and healthcare.
GA is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss.
AbbVie and REGENXBIO have formed a strategic partnership to develop and commercialise a potential gene therapy for wet age-related macular degeneration (AMD), diabetic retinopathy (DR) and other chronic retinal diseases.
Byoovis is designed for the treatment of wet age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to
Novartis and smartpatient have launched a new educational app experience for patients with age-related wet macular degeneration (AMD).
Beovu (brolucizumab) is the first anti-VEGF treatment to demonstrate superior resolution of retinal fluid compared to Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), according to Novartis.
Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
More from news
Approximately 1 fully matching, plus 128 partially matching documents found.
for advanced dry Age-related Macular Degeneration (AMD).
RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry
treatments for age-related macular degeneration (AMD).
to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).
330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
related macular degeneration.
While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.
Kaberry studied oncology, pharmacology and neurobiology, with a final year project on macular degeneration.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of
and macular degeneration.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...